Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02759588 · ClinicalTrials.gov registry record · Phase 1
Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer
A Phase 1 study, sponsored by Genelux Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT02759588 is a Phase 1 study that has completed, run by Genelux Corporation. The registered enrollment target is 46 participants.
The verdict
NCT02759588, a Phase 1 study, has completed, sponsored by Genelux Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Olvi-Vec oncolytic immunotherapy is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer and peritoneal carcinomatosis.
Interventions
- BIOLOGICAL Olvi-Vec
- DRUG Platinum-doublet with or without bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2016-05 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02759588
The ClinicalTrials.gov registry entry for NCT02759588 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genelux Corporation, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olvi-Vec is the first listed.
NCT02759588 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02759588 about?
NCT02759588 is a clinical study titled "Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer". The purpose of this study is to determine if Olvi-Vec oncolytic immunotherapy is well tolerated with anti-tumor activity in patients diagnosed with recurrent or refractory ovarian cancer and peritoneal carcinomatosis.
What is the current status of trial NCT02759588?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2016-05. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT02759588?
The interventions under investigation include: Olvi-Vec (BIOLOGICAL), Platinum-doublet with or without bevacizumab (DRUG).
Who is sponsoring clinical trial NCT02759588?
This trial is sponsored by Genelux Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.